Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_74b7b50944d8e1960440fb1f5440b7fd |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 |
filingDate |
2017-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fdf53b11a88e14d98fc2626fd239f45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_adcfbfef2db982b3d8f731c8f018be98 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e446826a8b90ca9e7479ff15b92a609d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_487a90cb5da5f9b52f7aae418dff0179 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8782948dbbee7044e445efebc4ebce8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cd10bb2779bbc593966bc8346ddae25 |
publicationDate |
2018-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2018064303-A1 |
titleOfInvention |
Methods for reducing liver fibrosis and treating lysosomal acid lipase deficiency in patients based on ishak fibrosis stage |
abstract |
The present invention provides methods of reducing liver fibrosis in a human patient with a lysosomal acid lipase (LAL) deficiency comprising administering sebelipase alfa to the patient, wherein the patient has been determined to have at least a one point reduction ( e.g. , a ≥ 1 point reduction or a ≥ 2 point reduction) in Ishak fibrosis stage after administration compared to a baseline Ishak fibrosis stage obtained from the patient prior to administration. Also provided are methods of treating a human patient with a lysosomal acid lipase (LAL) deficiency comprising administering sebelipase alfa to the patient, wherein the patient has been determined to have at least a one point reduction ( e.g ., a ≥ 1 point reduction or a ≥ 2 point reduction) in Ishak fibrosis stage after administration compared to a baseline Ishak fibrosis stage obtained from the patient prior to administration. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022122883-A1 |
priorityDate |
2016-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |